Detailansicht

Wissensnetz

Person

Panagiota Xanthouli (1985-)

Ärztin

Name	Panagiota Xanthouli
Zeit	1985- (Lebensdaten)
Ort	Mytilene (Geburtsort) Deutschland
Geschlecht	weiblich
Akademischer Grad bzw. Titel	Dr. med.
Beruf	Ärztin (charakteristischer Beruf)
Variante	P. Xanthouli
Beziehung	Thoraxklinik Heidelberg
Weitere Angaben	Diss. Medizinische Hochschule Hannover; Thoraxklinik Heidelberg
Datensatztyp	Person
GND-Nummer	1080490698
Datensatz-ID	1080490698
Beteiligt an alle anzeigen Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study Long-Term Safety, Outcome, and Clinical Effects of Subcutaneous and Intravenous Treprostinil Treatment in Patients with Severe Chronic Pulmonary Arterial Hypertension Oxygenated hemoglobin as prognostic marker among patients with systemic sclerosis screened for pulmonary hypertension Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri®): a prospective, 6-months, open label, observational, non-interventional study Long-Term Safety, Outcome, and Clinical Effects of Subcutaneous and Intravenous Treprostinil Treatment in Patients with Severe Chronic Pulmonary Arterial Hypertension Diagnose Algorithmus der pulmonalen Hypertonie und Screening-Verfahren Is iron deficiency caused by BMPR2 mutations or dysfunction in pulmonary arterial hypertension patients? Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity? Prognostic meaning of right ventricular function and output reserve in patients with systemic sclerosis Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity? Prognostic impact of hypochromic erythrocytes in patients with pulmonary arterial hypertension Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up Supervised Exercise Training in Patients with Chronic Thromboembolic Pulmonary Hypertension as Early Follow-Up Treatment after Pulmonary Endarterectomy: A Prospective Cohort Study Impact of SARS-CoV-2 pandemic on pulmonary hypertension out-patient clinics in Germany: a multi-centre study Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertension—A Genetic Study Right heart size and function significantly correlate in patients with pulmonary arterial hypertension – a cross-sectional study Autoantikörper gegen Angio- associated-migratory-cell Protein bei Patienten mit systemischem Lupus erythematodes

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Panagiota Xanthouli (1985-)

Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study

Long-Term Safety, Outcome, and Clinical Effects of Subcutaneous and Intravenous Treprostinil Treatment in Patients with Severe Chronic Pulmonary Arterial Hypertension

Oxygenated hemoglobin as prognostic marker among patients with systemic sclerosis screened for pulmonary hypertension

Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri®): a prospective, 6-months, open label, observational, non-interventional study

Long-Term Safety, Outcome, and Clinical Effects of Subcutaneous and Intravenous Treprostinil Treatment in Patients with Severe Chronic Pulmonary Arterial Hypertension

Diagnose Algorithmus der pulmonalen Hypertonie und Screening-Verfahren

Is iron deficiency caused by BMPR2 mutations or dysfunction in pulmonary arterial hypertension patients?

Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?

Prognostic meaning of right ventricular function and output reserve in patients with systemic sclerosis

Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension

Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?

Prognostic impact of hypochromic erythrocytes in patients with pulmonary arterial hypertension

Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up

Supervised Exercise Training in Patients with Chronic Thromboembolic Pulmonary Hypertension as Early Follow-Up Treatment after Pulmonary Endarterectomy: A Prospective Cohort Study

Impact of SARS-CoV-2 pandemic on pulmonary hypertension out-patient clinics in Germany: a multi-centre study

Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertension—A Genetic Study

Right heart size and function significantly correlate in patients with pulmonary arterial hypertension – a cross-sectional study

Autoantikörper gegen Angio- associated-migratory-cell Protein bei Patienten mit systemischem Lupus erythematodes